{"id":49452,"date":"2022-10-10T23:02:35","date_gmt":"2022-10-10T21:02:35","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\/"},"modified":"2022-10-10T23:02:35","modified_gmt":"2022-10-10T21:02:35","slug":"renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\/","title":{"rendered":"Renovacor Announces Upcoming Presentation at the 29th European Society of Gene & Cell Therapy Congress"},"content":{"rendered":"
\n

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced that the results of analytical and biophysical assays conducted as part of the company\u2019s chemistry, manufacturing, and controls (CMC) development process for REN-001 will be featured in an upcoming poster presentation at the 29th<\/sup> European Society of Gene & Cell Therapy (ESGCT) Congress. The congress is taking place from October 11 \u2013 14, 2022, at the Edinburgh International Conference Centre in Edinburgh, Scotland.\n<\/p>\n

<\/a><\/p>\n

\nREN-001 is an AAV-based gene therapy targeting BAG3-associated dilated cardiomyopathy (DCM), a severe form of heart failure. The upcoming poster (P046), titled, \u201cAnalytical and biophysical characterization of a rAAV9 vector for in-vivo gene therapy to treat dilated cardiomyopathy,\u201d will be presented from 5:30 \u2013 7:15 p.m. British Summer Time on October 14, 2022. The poster\u2019s presenting author is Angela Mohs, Ph.D., Director of Analytical Development at Renovacor.\n<\/p>\n

\nAbout Renovacor
\n
<\/b>Renovacor is a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. The company\u2019s lead program in BAG3-associated dilated cardiomyopathy (DCM) uses gene transfer technology to address the monogenic cause of this severe form of heart failure. Renovacor\u2019s vision is to bring life-changing therapies to patients living with serious genetic cardiovascular and related diseases, by developing medicines that target the underlying cause of disease and provide a transformative benefit and significant improvement to quality of life.\n<\/p>\n

\nForward-Looking Statements
\n
<\/b>This press release contains certain forward-looking statements within the meaning of the \u201csafe harbor\u201d provisions of the United States Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements generally are identified by the words \u201cbelieve,\u201d \u201cproject,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cintend,\u201d \u201cstrategy,\u201d \u201cfuture,\u201d \u201copportunity,\u201d \u201cplan,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201cwill be,\u201d \u201cwill continue,\u201d \u201cwill likely result,\u201d and similar expressions. These forward-looking statements are based upon current estimates and assumptions of the Company and its management and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition, the ability of the company to grow and manage growth, maintain relationships with customers and suppliers and retain its management and key employees; the Company’s ability to successfully advance its current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; the Company\u2019s ability to submit an IND related to REN-001 on its anticipated timeline, and any challenges related to the clearance of such IND by the FDA; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the Company may be adversely affected by other economic, business or competitive factors, including inflationary pressures; the Company\u2019s estimates of expenses and profitability; the evolution of the markets in which the Company competes; the ability of the Company to implement its strategic initiatives and continue to innovate its existing products; the ability of the Company to defend its intellectual property; the impact of the COVID-19 pandemic on the Company\u2019s business, supply chain and labor force; and the risks and uncertainties described in the \u201cRisk Factors\u201d section of the Company’s annual and quarterly and reports filed the Securities Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Renovacor assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Renovacor gives no assurance that it will achieve its expectations.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nBrooks Rahmer
\n
Renovacor, Inc.
\n
610-424-2627
\n
ir@renovacor.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced that the results of analytical and biophysical assays conducted as part of the company\u2019s chemistry, manufacturing, and controls (CMC) development process for REN-001 will … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49452","6":"format-standard","7":"category-industry"},"yoast_head":"\nRenovacor Announces Upcoming Presentation at the 29th European Society of Gene & Cell Therapy Congress - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Renovacor Announces Upcoming Presentation at the 29th European Society of Gene & Cell Therapy Congress - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass.–(BUSINESS WIRE)–Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced that the results of analytical and biophysical assays conducted as part of the company\u2019s chemistry, manufacturing, and controls (CMC) development process for REN-001 will ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-10T21:02:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221010005557\/en\/1374101\/21\/RENOVACOR-NO_TAG_%282%29_%281%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Renovacor Announces Upcoming Presentation at the 29th European Society of Gene & Cell Therapy Congress\",\"datePublished\":\"2022-10-10T21:02:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\\\/\"},\"wordCount\":702,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221010005557\\\/en\\\/1374101\\\/21\\\/RENOVACOR-NO_TAG_%282%29_%281%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\\\/\",\"name\":\"Renovacor Announces Upcoming Presentation at the 29th European Society of Gene & Cell Therapy Congress - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221010005557\\\/en\\\/1374101\\\/21\\\/RENOVACOR-NO_TAG_%282%29_%281%29.jpg\",\"datePublished\":\"2022-10-10T21:02:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221010005557\\\/en\\\/1374101\\\/21\\\/RENOVACOR-NO_TAG_%282%29_%281%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221010005557\\\/en\\\/1374101\\\/21\\\/RENOVACOR-NO_TAG_%282%29_%281%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Renovacor Announces Upcoming Presentation at the 29th European Society of Gene & Cell Therapy Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Renovacor Announces Upcoming Presentation at the 29th European Society of Gene & Cell Therapy Congress - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\/","og_locale":"en_US","og_type":"article","og_title":"Renovacor Announces Upcoming Presentation at the 29th European Society of Gene & Cell Therapy Congress - Pharma Trend","og_description":"CAMBRIDGE, Mass.–(BUSINESS WIRE)–Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced that the results of analytical and biophysical assays conducted as part of the company\u2019s chemistry, manufacturing, and controls (CMC) development process for REN-001 will ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-10T21:02:35+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221010005557\/en\/1374101\/21\/RENOVACOR-NO_TAG_%282%29_%281%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Renovacor Announces Upcoming Presentation at the 29th European Society of Gene & Cell Therapy Congress","datePublished":"2022-10-10T21:02:35+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\/"},"wordCount":702,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221010005557\/en\/1374101\/21\/RENOVACOR-NO_TAG_%282%29_%281%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\/","url":"https:\/\/pharma-trend.com\/en\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\/","name":"Renovacor Announces Upcoming Presentation at the 29th European Society of Gene & Cell Therapy Congress - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221010005557\/en\/1374101\/21\/RENOVACOR-NO_TAG_%282%29_%281%29.jpg","datePublished":"2022-10-10T21:02:35+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221010005557\/en\/1374101\/21\/RENOVACOR-NO_TAG_%282%29_%281%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221010005557\/en\/1374101\/21\/RENOVACOR-NO_TAG_%282%29_%281%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/renovacor-announces-upcoming-presentation-at-the-29th-european-society-of-gene-cell-therapy-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Renovacor Announces Upcoming Presentation at the 29th European Society of Gene & Cell Therapy Congress"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49452","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49452"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49452\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49452"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49452"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49452"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}